ReviewPloS one2016

Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China.

Shuyan Gu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.